// App-Quantinova.ai

P4-11-21 : Prevalence of circulating tumor cells (CTCs) after five years of zoledronate treatment in the adjuvant SUCCESS-A study

Researchers

Presenter

  • Rack B

Principal Investigators

  • Fasching PA

  • Hberle L

  • Albrecht S

  • Jger B

  • Fehm T

  • Mller V

  • Schneeweiss A

  • Friese K

  • Lichtenegger W

  • Beckmann MW

  • Janni WFriedl TRezai M

  • Hilfrich J

  • Tesch H

  • Heinrich G

  • Forstbauer H

  • Neugebauer J

  • Trapp E

Medical Centers

  • University Medical Center Charite, Berlin, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Fluorouracil

  • Adrucil injection

  • Gemcitabine

  • Zolendronic acid

  • Epirubicin

  • Docetaxel

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved